# Voyager Therapeutics (VYGR) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/VYGR
## Company Profile
- Ticker: VYGR
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Gene Therapy, CNS
## Stock Data
- Close: 2.15 USD
- Market cap: 216912420.32999998 USD
- Last updated: 2026-10-13
## Business Overview
### Neurologic Genetic Medicines
Voyager Therapeutics develops genetic medicines for neurologic diseases using human genetics and novel delivery technology. Its pipeline includes wholly owned and partnered programs.
### TRACER Capsid Platform
The TRACER platform discovers adeno-associated-virus capsids designed to reach the central nervous system after intravenous dosing. These capsids support gene-replacement and gene-silencing programs.
### Tau-Directed Alzheimer's Programs
VY1706 is a tau-silencing gene therapy approaching clinical development, while VY7523 is an anti-tau antibody already undergoing clinical evaluation in Alzheimer's disease.
### Partnered Friedreich's Ataxia Program
NBIB-223 is a Neurocrine-partnered gene therapy for Friedreich's ataxia that has completed IND-enabling toxicology.
## Why The Stock Is Moving

As of Oct 13, 2026, VYGR closed down 5.29% at $2.15. No new same-company headline was identified in the current news window.

## Future Catalysts

- IND application process for VY1706 in the second quarter of 2026.
- First-in-human dosing of VY1706 in Alzheimer's disease in the second half of 2026.
- Tau PET imaging efficacy data from the VY7523 study in the second half of 2026.
- Initiation of a clinical trial of NBIB-223 in Friedreich's ataxia in the second half of 2026, pending IND clearance.

## Recent News
- 2026-09-01 12:00 EST — [Voyager to Present at Upcoming Investor Conferences](https://biopharmsignal.com/news/VYGR/voyager-to-present-at-upcoming-investor-conferences-5c277d29) — Source: Voyager Therapeutics
- 2026-08-06 20:01 EST — [Voyager Reports Second Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/VYGR/voyager-reports-second-quarter-2026-financial-and-operating-results-b3aecbfa) — Source: Voyager Therapeutics
- 2026-07-13 12:01 EST — [Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026](https://biopharmsignal.com/news/VYGR/voyager-demonstrates-single-iv-dose-of-vy1706-well-tolerated-reduced-tau-in-6-mo-d6b19d18) — Source: Voyager Therapeutics
- 2026-06-29 12:01 EST — [Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026](https://biopharmsignal.com/news/VYGR/voyager-s-tau-targeted-gene-therapy-vy1706-for-alzheimer-s-disease-to-be-feature-7e183bb9) — Source: Voyager Therapeutics
- 2026-06-11 20:01 EST — [Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference](https://biopharmsignal.com/news/VYGR/voyager-to-present-at-h-c-wainwright-7th-annual-neuro-perspectives-hybrid-confer-3d59c3bb) — Source: Voyager Therapeutics